Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results

Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Eikelboom, 2010, Update on antithrombotic therapy. New anticoagulants, Circulation, 121, 1523, 10.1161/CIRCULATIONAHA.109.853119 Eriksson, 2009, Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development, Clin Pharmacokinet, 48, 1, 10.2165/0003088-200948010-00001 Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta‐analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003 Nagarakanti, 2011, Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion, Circulation, 123, 131, 10.1161/CIRCULATIONAHA.110.977546 Wang, 2004, Obesity and the risk of new‐onset atrial fibrillation, JAMA, 292, 2471, 10.1001/jama.292.20.2471 Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long‐term anticoagulant therapy (RE‐LY) trial, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Oldgren, 2011, Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE‐LY trial, Ann Intern Med, 155, 660, 10.7326/0003-4819-155-10-201111150-00004 Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE‐LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 Hohnloser, 2012, Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE‐LY (randomized evaluation of long‐term anticoagulation therapy) trial, Circulation, 125, 669, 10.1161/CIRCULATIONAHA.111.055970 Uchino, 2012, Dabigatran association with higher risk of acute coronary events. a meta‐analysis of noninferiority randomized controlled trials, Arch Intern Med, 172, 397, 10.1001/archinternmed.2011.1666 Colditz, 1989, How study design affects outcomes in comparisons of therapy. I: medical, Stat Med, 8, 441, 10.1002/sim.4780080408 Schulz, 1995, Empirical evidence of bias, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Stangier, 2010, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open‐label, parallel‐group, single‐centre study, Clin Pharmacokinet, 49, 259, 10.2165/11318170-000000000-00000 European Medicines Agency (EMEA). European public assessment report: Pradaxa. http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H‐829‐PI‐en.pdf Accessed 3 November 2009. Boehringer Ingelheim. Boehringer Ingelheim’s Pradaxa available in US pharmacies starting Wednesday, November 3 [press release]. http://www.prnewswire.com/news‐releases/boehringer‐ingelheims‐pradaxa‐available‐in‐us‐pharmacies‐starting‐Wednesday‐November‐3‐106474818.html. Accessed 1 November 2010.. Legrand, 2011, The use of dabigatran in elderly patients, Arch Intern Med, 171, 1285, 10.1001/archinternmed.2011.314 Stangier, 2008, Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate, Clin Pharmacokinet, 47, 285, 10.2165/00003088-200847050-00001 European Medicine Agency. Pradaxa summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000829/WC500041059.pdf. Accessed 10 February 2012. Harder, 2012, Renal profiles of anticoagulants, J Clin Pharmacol, 52, 964, 10.1177/0091270011409231 2009 Hylek, 2007, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation, Circulation, 115, 2689, 10.1161/CIRCULATIONAHA.106.653048 Poli, 2009, Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention, Thromb Haemost, 101, 367, 10.1160/TH08-09-0592 Poli, 2012, Impact of glomerular filtration estimate on bleeding risk in very old patients treated with VKA: results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics), Thromb Haemost, 107, 1100, 10.1160/TH11-10-0721 Liesenfeld, 2011, Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial, J Thromb Haemost, 9, 2168, 10.1111/j.1538-7836.2011.04498.x Mega, 2012, ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Eerenberg, 2011, A randomized, placebo‐controlled, crossover study in healthy subjects reversal of rivaroxaban and dabigatran by prothrombin complex concentrate, Circulation, 124, 1573, 10.1161/CIRCULATIONAHA.111.029017 BoehringerIngelheim Pharmaceuticals. RELY‐ABLE long term multi‐center extension of dabigatran treatment in patients with atrial fibrillation who completed RE‐LY trial. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT00808067?term=NCT00808067&rank=1; accessed 15 January 2012.